TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11730261

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9431836

Group type: EXPERIMENTAL
Intervention: Clinical trial format presentation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient data format presentation
Number of subjects: 50
Study: 8472523

Group type: EXPERIMENTAL
Intervention: Meclofenamic acid (200 mg b.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 30
Study: 3718377

Group type: EXPERIMENTAL
Intervention: 1 mg scopolamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine with 5 mg d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine and scopolamine with d-amphetamine (after discontinuation on day 5)
Number of subjects: 0
Study: 29756213

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xenogeneic Collagen Matrix (XCM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No Graft (NG)
Number of subjects: 60
Study: 27261817

Group type: EXPERIMENTAL
Intervention: ZP‐025 (Monurelle Biogel®) vaginal gel, 1 or 2 times/daily intra‐vaginally for about 23 intermenstrual days
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ZP‐025 (Monurelle Biogel®) vaginal gel
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (no treatment, lubricants on demand allowed)
Number of subjects: 95
Study: 24944128

Group type: EXPERIMENTAL
Intervention: Football training (FT); 3 × 40 min of small-sided football training per week for 10 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (CON); maintained usual activities
Number of subjects: 97
Study: 22755467

Group type: EXPERIMENTAL
Intervention: Explicit practice
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Implicit practice
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sequential practice (implicit first and then explicit)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (measurements only)
Number of subjects: 60
Study: 21084037

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment (FK506)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate ointment (MPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (MPA + FK506)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 18295469

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% with fentanyl 1 microg/mL at 8 mL/h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All three regimens
Number of subjects: 102
Study: 15914548

Group type: EXPERIMENTAL
Intervention: FE(NO) measurements
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional guidelines (control group)
Number of subjects: 97
Study: 11936565

Group type: EXPERIMENTAL
Intervention: Immediate-release formulation (500 mg IR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Modified-release formulation (500 mg MR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Modified-release formulation (750 mg MR)
Number of subjects: 12
Study: 10892480

Group type: EXPERIMENTAL
Intervention: Viscoat (3% sodium hyaluronate and 4% chondroitin sulfate)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Provisc (1% sodium hyaluronate)
Number of subjects: 82
Study: 8821268

Group type: EXPERIMENTAL
Intervention: Tendon defect left open (Group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Tendon defect closed (Group B)
Number of subjects: 61
Study: 2140331

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: Josamycin 500 mg three times daily
Number of subjects: 103
Study: 6815790

Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low dose methylprednisolone (control)
Number of subjects: 30
Study: 6238861

Group type: EXPERIMENTAL
Intervention: C 48.401‐Ba cream (0.05% halomethasone)
Number of subjects: 117

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ointment containing 0.05% halomethasone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ointment containing 0.1% betamethasone valerate
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: C 48.401‐Ba ointment (0.05% halomethasone)
Number of subjects: 117

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate ointment
Number of subjects: 117
Study: 31381428

Group type: EXPERIMENTAL
Intervention: Warning outside the comfort boundary (CB) at time to collision (TTC) of 1.7 seconds
Number of subjects: 31

Group type: COMPARATOR
Intervention: Warning inside the comfort boundary (CB) at TTC of 2.6 seconds
Number of subjects: 31
Study: 30384555

Group type: EXPERIMENTAL
Intervention: Kinesiotaping in addition to tendon and nerve gliding exercises
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tendon and nerve gliding exercises
Number of subjects: 21
Study: 27548106

Group type: EXPERIMENTAL
Intervention: Pulsatile cortisol infusion
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mifepristone (GR antagonist)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Eplerenone (MR antagonist)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CRH-arginine vasopressin stimulation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Withdrawal vs addback of sex steroids
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison of ACTH secretion between men and women
Number of subjects: 41
Study: 25231095

Group type: EXPERIMENTAL
Intervention: CD133(+) cells
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 28
Study: 22492430

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Epicardial RFA
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Procedures with 3D electroanatomic mapping
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Any ablation strategy
Number of subjects: 87
Study: 19268928

Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate (25 mg/day) and vitamin E (400 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and vitamin E
Number of subjects: 60
Study: 18624803

Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions over 3 months)
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Control (routine care alone)
Number of subjects: 1613
Study: 16115336

Group type: EXPERIMENTAL
Intervention: Danish meat diet (60 g of pork meat)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Polish meat diet (60 g of pork meat)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 19
Study: 11832527

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (goals of at least 7% weight loss and at least 150 minutes of physical activity per week)
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study: 10026394

Group type: EXPERIMENTAL
Intervention: UVA irradiation at low dose (20 J/cm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UVA irradiation at high dose (60 J/cm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UVA irradiation (both doses)
Number of subjects: 0
Study: 7473528

Group type: EXPERIMENTAL
Intervention: Phosphoramidon (combined inhibitor of endothelin converting enzyme and neutral endopeptidase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiorphan (selective inhibitor of NEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BQ-123 (selective ETA receptor antagonist)
Number of subjects: 0
Study: 2263574

Group type: EXPERIMENTAL
Intervention: Pamphlet plus notification letter
Number of subjects: 161

Group type: COMPARATOR
Intervention: Notification letter only
Number of subjects: 161
Study: 6995038

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30628483

Group type: EXPERIMENTAL
Intervention: Group-based exercise programme with psychological intervention to change SPA (n=46)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Group-based exercise programme without psychological intervention to change SPA (n=38)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (n=84)
Number of subjects: 84
Study: 30022753

Group type: EXPERIMENTAL
Intervention: rhTPO + DXM treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: DXM treatment
Number of subjects: 58
Study: 27553827

Group type: EXPERIMENTAL
Intervention: Oxygen alone
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Metoclopramide plus oxygen
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Metamizole plus oxygen
Number of subjects: 117
Study: 25123172

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation ON
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sacral neuromodulation OFF
Number of subjects: 0
Study: 22380743

Group type: EXPERIMENTAL
Intervention: (R)-warfarin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: (S)-warfarin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Protein binding of (R)- and (S)-warfarin
Number of subjects: 72
Study: 19419364

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg/kg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 105
Study: 17213239

Group type: EXPERIMENTAL
Intervention: Assertive therapy (standing on the fractured limb and walking in parallel bars)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment (immobilization under skin traction and gradual use of a wheelchair)
Number of subjects: 20
Study: 16094658

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VXR)
Number of subjects: 3097

Group type: COMPARATOR
Intervention: Conventional antidepressants (CA)
Number of subjects: 3097
Study: 11244392

Group type: EXPERIMENTAL
Intervention: Focused short-term group therapy (10 sessions of 1.5 hours per week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (received group therapy 5 months after the first group)
Number of subjects: 14
Study: 9227716

Group type: EXPERIMENTAL
Intervention: PGD2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pre-inhalation of LTD4
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pre-inhalation of methacholine
Number of subjects: 20
Study: 7678684

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg b.i.d. titrated to 75 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Verapamil SR (120 mg q.d. titrated to 360 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Captopril (compared to placebo)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Verapamil (compared to placebo)
Number of subjects: 23
Study: 2889081

Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant alpha 2‐interferon (r‐IFN) ('Roferon') 10 X 10(6) IU/m2 thrice weekly for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vitamin B complex
Number of subjects: 24
Study: 28521579

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) - 8 weekly sessions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 15
Study: 28011513

Group type: EXPERIMENTAL
Intervention: Tumescent Anesthesia (TA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no Tumescent Anesthesia)
Number of subjects: 30
Study: 25579466

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (two nights of delayed bedtime and four hours sleep)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nine hours sleep (control group)
Number of subjects: 33
Study: 23705645

Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index (LGI) diet
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional Healthy Dietary Recommendation (CHDR)
Number of subjects: 77
Study: 21131377

Group type: EXPERIMENTAL
Intervention: HFA OP
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: GPA
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: GPA2
Number of subjects: 303
Study: 19399268

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix 0.25 mg/day) until the day of hCG administration (Group A, 66 cycles)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix 0.25 mg/day) until the day before hCG administration (Group B, 26 cycles)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 65
Study: 16890670

Group type: EXPERIMENTAL
Intervention: 20 mg toremifene
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: 40 mg toremifene
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: 60 mg toremifene
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 14728938

Group type: EXPERIMENTAL
Intervention: HIT-91 therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benign brain tumours (BBT)
Number of subjects: 0
Study: 11560163

Group type: EXPERIMENTAL
Intervention: 0.005% calcipotriol ointment
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% coal tar ointment
Number of subjects: 10
Study: 8811478

Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Systemic metronidazole
Number of subjects: 46

Group type: COMPARATOR
Intervention: Supplementary surgery or chemotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Complex therapy
Number of subjects: 46
Study: 1529416

Group type: EXPERIMENTAL
Intervention: Pinacidil 12.5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3908727

Group type: EXPERIMENTAL
Intervention: S6472 (750 mg, 2 times/day)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) (500 mg, 3 times/day)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Cephalexin (CEX) (500 mg, 4 times/day)
Number of subjects: 388
Study: 30675739

Group type: EXPERIMENTAL
Intervention: levomilnacipran ER (40, 80, or 120 mg/d)
Number of subjects: 644

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: levomilnacipran ER
Number of subjects: 644
Study: 29532981

Group type: EXPERIMENTAL
Intervention: HAM-RS2
Number of subjects: 46

Group type: COMPARATOR
Intervention: Wheat-flour (Control)
Number of subjects: 46
Study: 27494037

Group type: EXPERIMENTAL
Intervention: Methadone (Met)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fentanyl (Fen)
Number of subjects: 52
Study: 25363118

Group type: EXPERIMENTAL
Intervention: Reality therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 60
Study: 23102380

Group type: EXPERIMENTAL
Intervention: Bivalirudin + Gp IIb/IIIa inhibitor (tirofiban)
Number of subjects: 101

Group type: COMPARATOR
Intervention: UFH + Gp IIb/IIIa inhibitor (tirofiban)
Number of subjects: 101
Study: 20954776

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 0
Study: 18853560

Group type: EXPERIMENTAL
Intervention: Masking by noise
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Paracontrast and metacontrast masking
Number of subjects: 2
Study: 16519386

Group type: COMPARATOR
Intervention: Standard Propofol (average particle size 193.3 nm) with 2 ml NaCl 0.9%
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Standard Propofol (average particle size 193.3 nm) with 2 ml lidocaine 2%
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml NaCl 0.9%
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml lidocaine 2%
Number of subjects: 388
Study: 12627214

Group type: EXPERIMENTAL
Intervention: Urethral catheter removal on postoperative day (POD) 3
Number of subjects: 22
Study: 10356941

Group type: EXPERIMENTAL
Intervention: Vitamin supplement (Vitality Roeder 2000 Junior)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7644858

Group type: EXPERIMENTAL
Intervention: High titre vaccines
Number of subjects: 0
Study: 1487546

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-carbohydrate meal
Number of subjects: 28
Study: 4030162

Group type: EXPERIMENTAL
Intervention: Morning dose (7:00 a.m.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Evening dose (7:00 p.m.)
Number of subjects: 16
Study: 29747311

Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) as first-line therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) as non-first-line therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) in taxane-naïve patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) in taxane-pretreated patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Abraxane (reference drug)
Number of subjects: 40
Study: 26801885

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 40
Study: 23740477

Group type: EXPERIMENTAL
Intervention: 120 mg/day Eleutherococcus senticosus root extract (ES)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 2-day professional stress management training (SMT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination of both (COM)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 144
Study: 21123766

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 40 mg/day
Number of subjects: 22
Study: 19652945

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8 g kg(‐1) day(‐1))
Number of subjects: 112

Group type: COMPARATOR
Intervention: Normal-protein diet (1.2 g kg(‐1) day(‐1))
Number of subjects: 112
Study: 17960012

Group type: EXPERIMENTAL
Intervention: TPF (docetaxel and cisplatin on day 1; fluorouracil by continuous infusion, days 1 to 5)
Number of subjects: 358

Group type: COMPARATOR
Intervention: PF (cisplatin and fluorouracil every 3 weeks for four cycles)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 358

Group type: COMPARATOR
Intervention: PF
Number of subjects: 358
Study: 15476608

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Early Thrombosis
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Major Adverse Cardiac Events
Number of subjects: 2082
Study: 12170929

Group type: EXPERIMENTAL
Intervention: Kato-Katz technique for STH prevalence assessment
Number of subjects: 0
Study: 9294786

Group type: EXPERIMENTAL
Intervention: Educational seminars on skin cancer control (two 1-hour sessions)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 82
Study: 8373716

Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg twice daily for 3 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg twice daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3456816

Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (PGD2) co-injected with histamine (2.5 nmol) at varying molar ratios (15 to 1215)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine (2.5 nmol)
Number of subjects: 0
Study: 31402740

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aussie current
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TENS, IFC, Aussie current
Number of subjects: 120
Study: 30156192

Group type: EXPERIMENTAL
Intervention: Filtek‐Z550 (3M/ESPE) with Adper™ Single Bond 2 (3M/ESPE) etch and rinse adhesive
Number of subjects: 23

Group type: COMPARATOR
Intervention: Charisma‐Diamond (Heraeus Kulzer) with Gluma2 Bond (Heraeus Kulzer) etch and rinse adhesive
Number of subjects: 23
Study: 28033693

Group type: EXPERIMENTAL
Intervention: Morphine suppository (10 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac suppository (100 mg)
Number of subjects: 100
Study: 24199687

Group type: EXPERIMENTAL
Intervention: Iron supplementation (n=36)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Folate supplementation (n=36)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (n=36)
Number of subjects: 108
Study: 23296213

Group type: EXPERIMENTAL
Intervention: CM(attendance)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CM(weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CON
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CM(behavior)
Number of subjects: 30
Study: 21330809

Group type: EXPERIMENTAL
Intervention: Simulation-based training (SBT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional tutorial-based interactive education training (IET)
Number of subjects: 27
Study: 18712029

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate lotion 0.05%
Number of subjects: 20

Group type: COMPARATOR
Intervention: OTC anti‐itch preparation containing benzyl alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Petrolatum ointment
Number of subjects: 20